Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion
04:08pm, Monday, 17'th Oct 2022 Zacks Investment Research
Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.
Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion
01:33pm, Monday, 17'th Oct 2022
Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.
Novartis (NVS) Stock Moves -0.58%: What You Should Know
10:15pm, Friday, 14'th Oct 2022 Zacks Investment Research
In the latest trading session, Novartis (NVS) closed at $75.57, marking a -0.58% move from the previous day.
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv
04:06pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
Merck (MRK) Posts Positive Results From PAH Drug Study
03:27pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.
Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?
03:52pm, Monday, 10'th Oct 2022 Zacks Investment Research
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
GSK's (GSK) Boostrix Gets FDA Nod for Pertussis in Newborns
03:21pm, Monday, 10'th Oct 2022 Zacks Investment Research
Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.
Mark Cuban Says Americans Shouldn't Have To Pick Between Rent, Food Or Medicine
07:30pm, Sunday, 09'th Oct 2022 Benzinga
This article was originally published on July 29, 2022.
Famed billionaire, entrepreneur and Dallas Maverick’s owner Mark Cuban thinks Americans shouldn’t have to pick between necessities such as
The 12 Best High-Yield Dividend Aristocrats For What's Coming Next
11:20am, Saturday, 08'th Oct 2022 Seeking Alpha
The market is off to the best start to October since 1930, with a 6% rally to kick off the month and this is very likely the 5th bear market rally. Click here to read more.
2 Cathie Wood Stocks That Are Beating the Market This Year
08:15pm, Friday, 07'th Oct 2022 The Motley Fool
One is doing much better than the other year to date, but they both have solid prospects ahead.
BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency
04:31pm, Friday, 07'th Oct 2022 Zacks Investment Research
BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs and redirect them toward its operating expenses.
Lilly's (LLY) Diabetes Drug Gets FDA Fast Track Tag for Obesity
03:43pm, Friday, 07'th Oct 2022 Zacks Investment Research
Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.
The Zacks Analyst Blog Highlights Novartis, Lowe's, The Goldman Sachs, Twitter and Xcel Energy
11:33am, Friday, 07'th Oct 2022 Zacks Investment Research
Novartis, Lowe's, The Goldman Sachs, Twitter and Xcel Energy are part of the Zacks top Analyst Blog.
Top Research Reports for Novartis, Lowe's & Goldman Sachs
08:41pm, Thursday, 06'th Oct 2022 Zacks Investment Research
Today's Research Daily features new research reports on 12 major stocks, including Novartis AG (NVS), Lowe's Companies, Inc. (LOW) and The Goldman Sachs Group, Inc. (GS).
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
03:02pm, Thursday, 06'th Oct 2022 Zacks Investment Research
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.
